Angina News and Research RSS Feed - Angina News and Research

Angina is chest pain or discomfort that occurs when an area of your heart muscle doesn't get enough oxygen-rich blood. Angina may feel like pressure or squeezing in your chest. The pain also may occur in your shoulders, arms, neck, jaw, or back. It can feel like indigestion.
Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Taxus Cardium Pharmaceuticals Group Inc. will report today at the Biotechnology Industry Organization’s 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx Ad5FGF-4, Cardium Therapeutics’ angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease. [More]

Neovasc's common shares to commence trading on TSX

Neovasc Inc. ("Neovasc" or the "Company") today announced that effective at market opening on June 23, 2014, Neovasc's common shares will commence trading on the Toronto Stock Exchange (the "TSX") under the Company's current trading symbol of "NVC". [More]
Study demonstrates cost-effectiveness of Ottawa Model for Smoking Cessation

Study demonstrates cost-effectiveness of Ottawa Model for Smoking Cessation

In a recent study published in Tobacco Control, researchers at the University of Ottawa Heart Institute have demonstrated the cost-effectiveness of the Ottawa Model for Smoking Cessation (OMSC), an intervention that includes in-hospital counseling, pharmacotherapy and post-hospital follow-up, compared to usual care among smokers hospitalized with acute myocardial infarction, unstable angina, heart failure, and chronic obstructive pulmonary disease. [More]
Blood pressure has heterogeneous associations with cardiovascular diseases

Blood pressure has heterogeneous associations with cardiovascular diseases

The associations between blood pressure and cardiovascular disease are variable, reveals a large study that highlights the impact of angina and heart failure. [More]
Systolic, diastolic blood pressures may have different effects on different types of cardiovascular diseases

Systolic, diastolic blood pressures may have different effects on different types of cardiovascular diseases

Raised systolic and diastolic blood pressures may have different effects on different types of cardiovascular diseases and at different ages, according to new research involving 1.25 million patients from primary care practices in England published in a special themed issue of The Lancet. [More]
Sanofi and Lilly announces agreement to pursue regulatory approval of Cialis

Sanofi and Lilly announces agreement to pursue regulatory approval of Cialis

Sanofi and Eli Lilly and Company today announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). [More]
Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

Micell Technologies, Inc. today announced that long-term clinical outcomes from its DESSOLVE I and II clinical trials were presented at the EuroPCR conference in Paris, France this week. [More]
Neovasc  reports record revenues in Q1 2014

Neovasc reports record revenues in Q1 2014

Neovasc Inc. ("Neovasc" or the "Company"), today announced financial results for the three months ended March 31, 2014. "The first quarter of 2014 was marked by major developments at Neovasc," noted Alexei Marko, chief executive officer of Neovasc. [More]
Endo acquires worldwide rights to Zogenix' sumatriptan injection

Endo acquires worldwide rights to Zogenix' sumatriptan injection

Endo International plc announced today that affiliates of the company have completed the acquisition of worldwide rights to Sumavel® DosePro® (sumatriptan injection), a needle-free delivery system for subcutaneous use, from Zogenix, Inc, for $85 million in cash and rights to additional cash payments based on the achievement of certain commercial milestones. [More]
FDA allows CryoLife to begin PerClot clinical trial in the U.S.

FDA allows CryoLife to begin PerClot clinical trial in the U.S.

CryoLife, Inc., a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has received approval of its Investigational Device Exemption (IDE) for PerClot from the United States Food and Drug Administration. [More]
Clonidine increases hypotension and non-fatal cardiac arrest after noncardiac surgery

Clonidine increases hypotension and non-fatal cardiac arrest after noncardiac surgery

Clonidine - a drug that reduces blood pressure and heart rate - increased rates of clinically concerning hypotension and non-fatal cardiac arrest after noncardiac surgery, according to the POISE-2 trial presented at the American College of Cardiology's 63rd Annual Scientific Session. [More]
Aleglitazar drug does not reduce risk of cardiovascular events in patients with type 2 diabetes

Aleglitazar drug does not reduce risk of cardiovascular events in patients with type 2 diabetes

Use of the drug aleglitazar, which has shown the ability to lower glucose levels and have favorable effects on cholesterol, did not reduce the risk of cardiovascular death, heart attack or stroke among patients with type 2 diabetes and recent heart attack or unstable angina, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions. [More]
Takeda to present results from global EXAMINE CV safety outcomes trial at ACC 2014

Takeda to present results from global EXAMINE CV safety outcomes trial at ACC 2014

Takeda Pharmaceuticals Company Limited will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial in a poster session at the American College of Cardiology’s 63rd Annual Scientific Session in Washington, DC. [More]
Study: Daily dietary supplements not associated with reduced risk for CVD in elderly

Study: Daily dietary supplements not associated with reduced risk for CVD in elderly

Daily dietary supplements of omega-3 polyunsaturated fatty acids (also found in fish) or lutein and zeaxanthin (nutrients found in green leafy vegetables) were not associated with reduced risk for cardiovascular disease (CVD) in elderly patients with the eye disease age-related macular degeneration. [More]
New standard for U.S. heart transplantation

New standard for U.S. heart transplantation

The Cedars-Sinai Heart Institute has set a new standard for U.S. heart transplantation by completing 117 adult heart transplants and two adult heart-lung transplants, for a total of 119 adult heart transplants in a single year. The previous number set in 2005, was 98 adult heart transplants performed in one year. [More]
Study: Men are more likely to receive faster care for heart attacks and angina than women

Study: Men are more likely to receive faster care for heart attacks and angina than women

A new study indicates that in younger adults experiencing heart attacks and angina, men are more likely to receive faster care compared with women. The study, published in CMAJ (Canadian Medical Association Journal) also found that gender-related factors affected access to care for both men and women. [More]
Treating long wait-times dictate long-term success of spinal cord stimulation therapy

Treating long wait-times dictate long-term success of spinal cord stimulation therapy

Success rates soared to 75% for patients who waited less than 2 years for a spinal cord stimulator (SCS) implant, compared with 15% for patients whose implants happened 20 years after the onset of pain, according to a retrospective analysis. [More]
POZEN reports total revenue of $4.7 million for fourth quarter 2013

POZEN reports total revenue of $4.7 million for fourth quarter 2013

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the fourth quarter and year ended December 31, 2013. [More]
National Audit of PCI reveals patients with acute coronary syndromes treated more quickly using PCI

National Audit of PCI reveals patients with acute coronary syndromes treated more quickly using PCI

Expansion in the use of Percutaneous Coronary Intervention - the minimally invasive surgery performed on heart patients instead of using drugs - is seeing more patients with acute coronary syndromes treated more quickly, according to the latest National Audit of PCI. [More]
New easy-to-use risk calculator helps predict heart failure patients' chances of survival

New easy-to-use risk calculator helps predict heart failure patients' chances of survival

A UCLA team has developed an easy-to-use "risk calculator" that helps predict heart failure patients' chances of survival for up to five years and assists doctors in determining whether more or less aggressive treatment is appropriate. [More]